CD8A and bone cancer: CD3+, CD4+, CD8+ and CD4+/CD8+ values in Group-A were not significantly improved compared with before treatment, while CD3+, CD4+ levels and CD4+/CD8+ values were increased and CD8+ value was decreased in Group-B, suggesting that neoadjuvant chemotherapy combined with customized tumor-type TKA can remarkably ameliorate the immune function of patients with malignant bone tumors around the knee joint, which is consistent with the results of Kawai A et al.20